Xeris Biopharma Holdings (XERS) Goodwill & Intangibles (2021 - 2026)

Xeris Biopharma Holdings' Goodwill & Intangibles history runs 6 years deep, the most recent figure standing at $108.2 million for Q1 2026.

• Quarterly Goodwill & Intangibles fell 9.11% year-over-year to $108.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $108.2 million (down 9.11% YoY) and the FY2025 annual result came in at $110.9 million, down 8.9% from the prior year.
• Goodwill & Intangibles was $108.2 million for Q1 2026 at Xeris Biopharma Holdings, down from $110.9 million in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $151.6 million in Q1 2022 and bottomed at $108.2 million in Q1 2026.
• A 5-year average of $129.9 million and a median of $129.9 million in 2024 frame the typical range for Goodwill & Intangibles.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles retreated 7.03% — and 2026, when it fell 9.11%.
• Xeris Biopharma Holdings' Goodwill & Intangibles stood at $143.5 million in 2022, then dropped by 7.56% to $132.6 million in 2023, then retreated by 8.18% to $121.8 million in 2024, then fell by 8.9% to $110.9 million in 2025, then decreased by 2.44% to $108.2 million in 2026.
• Business Quant data shows XERS's Goodwill & Intangibles at $108.2 million in Q1 2026, $110.9 million in Q4 2025, and $113.6 million in Q3 2025.